|
Patent landscape, scope, and claims: |
Executive summary: US Patent 9,782,349 claims a narrow set of irinotecan liposome compositions and a specific manufacturing loading process that uses sulfated sugars (notably sucrose sulfates) as intraliposomal cargo and substituted ammonium compounds (diethylammonium and/or triethylammonium) during vesicle formation, then loads irinotecan above the lipid phase transition temperature to achieve high loading and in vivo retention. The claims also tightly recite quantitative in vivo performance: at least 70% of irinotecan remains encapsulated after 8 hours in CD-1 mouse blood, and in dependent claims lock lipid composition to DSPC:cholesterol = 3:2 and sulfonation strength to sulfated sugar pKa ≤ 3. The practical patent landscape risk is that claim scope is likely enforceable mainly where a product’s functional performance (≥85% loading; ≥70% encapsulated at 8 hours) and process elements (ammonium-containing vesicle formation + loading above transition temperature) are met, while design-arounds shifting either the sulfated sugar identity/pKa, the ammonium identity, the lipid molar ratio, or the loading temperature regime create plausible non-infringement paths.
US Patent 9,782,349 scope and claims analysis: irinotecan liposome with sulfated sugar and ammonium loading
What is the independent claim actually protecting (Claim 1)?
Claim 1 is a composition claim that is explicitly tied to a process by which the composition is made, via “wherein the composition is obtainable by a process comprising” steps (a) and (b). That matters because it converts part of the claim into a process-dependent product-by-process construct.
Core elements of Claim 1
- Product structure
- A liposome (lipid vesicle).
- Encapsulates irinotecan.
- Also encapsulates a sulfated sugar.
- Cargo loading and retention performance
- Step (b) loads irinotecan by contacting the vesicles with irinotecan at a temperature above the phase transition temperature of the lipid vesicle.
- Achieves at least 85% loading of irinotecan into the liposome.
- Performance test: ≥70% of irinotecan remains encapsulated after 8 hours in the blood of a CD-1 mouse.
- Manufacturing constraint during vesicle formation
- Step (a) forms vesicles encapsulating:
- sulfated sugar, and
- one or more substituted ammonium compounds selected from:
- diethylammonium and/or triethylammonium,
- in a lipid composition comprising lipid components that form the vesicle.
Implied technical “pressure points”
- Temperature regime above phase transition is a key discriminant. If a competitor loads below Tm or uses alternative loading methods (e.g., remote loading via transmembrane gradients created by other ions), infringement risk drops.
- The use of diethylammonium/triethylammonium during vesicle formation with sulfated sugar defines an internal environment likely tied to irinotecan partitioning and trapping.
- The claim requires a measured in vivo encapsulation retention after 8 hours in mouse blood, which is not a generic liposome trait. Products can be compositionally similar yet fail the test.
How dependent claims narrow the estate (Claims 2–5, 7–10)
Key dependent constraints:
- Claim 2: sulfated sugar has pKa ≤ 3.
- Claim 3: vesicle lipids are specifically DSPC + cholesterol at 3:2 molar ratio.
- Claim 4: sulfated sugar is limited to:
- sucrose hexasulfate
- sucrose heptasulfate
- sucrose octasulfate
- Claim 5: further narrows to sucrose octasulfate.
Together, these define a tight corridor:
- both the identity (hexasulfate/heptasulfate/octasulfate) and the acid strength proxy (pKa ≤ 3) are claimed, and
- lipid composition is fixed in at least one path (DSPC:cholesterol 3:2).
What Claim 6 adds (process-by-process variant)
Claim 6 largely restates Claim 1 but makes the sulfated sugar identity explicit (hexasulfate/heptasulfate/octasulfate) while preserving the process requirements:
- vesicle formation with sulfated sugar + diethylammonium/triethylammonium,
- irinotecan contacting above phase transition,
- ≥85% loading.
This strengthens enforceability where a product clearly uses those sulfated sugars and follows that manufacturing pathway.
What Claim 11 protects (functional composition without process steps)
Claim 11 shifts from the detailed process constraints to a functional composition standard:
- a liposome with irinotecan and a sulfated sugar,
- with the performance requirement:
- ≥70% irinotecan remains encapsulated after 8 hours in CD-1 mouse blood.
This can be strategically important in enforcement because it potentially reduces the need to prove each process step if a product is shown to meet the encapsulation retention standard. Still, the claim is likely construed in light of the spec describing how to reach that threshold.
What Claim 12 and Claim 16 lock down: the measurement method
Claim 12 is a method claim embedded in the composition context: the amount of encapsulated irinotecan is “determined by a method comprising” a specific radio-labeling and blood processing protocol. It recites:
- radioactive labeled irinotecan liposome administered to six-week-old female CD-1 mice
- tail vein injection at 10 mg/kg (0.2 mg CPT-11/mouse)
- anesthetize and exsanguinate at 8 hours
- collect blood into heparinized syringes, dilute/hold in specified buffers with EDTA
- centrifugation at 9,000 g for 5 minutes
- assay via fluorometric assay with quenching-corrected radioactivity scintillation counting
- compute percent encapsulated by normalization to injected liposomes (percent injected dose remaining is computed assuming 100% bolus enters circulation)
Claim 16 is a corresponding dependent claim for the pharmaceutical composition version.
Practical impact:
- If a competitor challenges the measurement as not using this exact protocol, that affects how reliably a lab result can be used to establish the ≥70% requirement for infringement. The presence of this detailed method suggests the patent anticipates and neutralizes typical assay disputes.
What Claim 15 and Claim 17 cover: pharmaceutical compositions with fixed excipient systems
- Claim 15: pharmaceutical composition comprising liposomes encapsulating irinotecan and sucrose hexasulfate.
- Claim 17: a more complete packaging of features:
- DSPC:cholesterol 3:2
- sulfated sugar pKa ≤ 3
- irinotecan retention ≥70% at 8 hours in CD-1 mouse blood
These claims tie the protected product into a “ready-to-market style” pharmaceutical composition form, at least conceptually. Their scope likely overlaps with any finished product containing that liposome system.
Which elements are essential vs. optional in US Patent 9,782,349? A claim-by-claim infringement map
Feature lattice
The following table translates the claim set into essential/optional elements. “Must” means required for that claim.
| Claim |
Liposome + irinotecan |
Intraliposomal sulfated sugar |
Ammonium during vesicle formation (diethylammonium / triethylammonium) |
Loading above phase transition |
Loading level ≥85% |
Retention in CD-1 blood ≥70% at 8h |
Sulfated sugar type / pKa limits |
DSPC:Chol 3:2 |
| 1 |
Must |
Must |
Must |
Must |
Must |
Must |
Not limited |
Optional (not required) |
| 2 |
Must |
Must (pKa ≤3) |
Must |
Must |
Must |
Must |
Must |
Optional |
| 3 |
Must |
Must |
Must |
Must |
Must |
Must |
Not limited |
Must |
| 4 |
Must |
Must (hex/hept/oct sulfates) |
Must |
Must |
Must |
Must |
Must |
Optional |
| 5 |
Must |
Must (sucrose octasulfate) |
Must |
Must |
Must |
Must |
Must |
Optional |
| 6 |
Must |
Must (hex/hept/oct sulfates) |
Must |
Must |
Must |
Must |
Must |
Optional |
| 7 |
Must |
Must (pKa ≤3) |
Must |
Must |
Must |
Must |
Must |
Optional |
| 8 |
Must |
Must |
Must |
Must |
Must |
Must |
Must |
Must |
| 9 |
Must |
Must |
Must |
Must |
Must |
Must |
Must (via claim 8) |
Must |
| 10 |
Must |
Must (pKa ≤3) |
Must |
Must |
Must |
Must |
Must |
Must |
| 11 |
Must |
Must |
Not required in text |
Not required in text |
Not required in text |
Must |
Not limited |
Optional |
| 12 |
Must (indirect) |
Must |
Not required in text |
Not required in text |
Not required in text |
Must via ≥70% test |
Not limited |
Optional |
| 13 |
Must (via claim 11) |
Must (pKa ≤3) |
Not required in text |
Not required in text |
Not required in text |
Must |
Must |
Optional |
| 14 |
Must (via claim 13) |
Must (pKa ≤3) |
Not required in text |
Not required in text |
Not required in text |
Must |
Must |
Must |
| 15 |
Must |
Must (sucrose hexasulfate) |
Not stated |
Not stated |
Not stated |
Not stated |
Must |
Optional |
| 16 |
Must (indirect) |
Must (sucrose hexasulfate) |
Not stated |
Not stated |
Not stated |
Must via method |
Must |
Optional |
| 17 |
Must |
Must (pKa ≤3) |
Not stated |
Not stated |
Not stated |
Must |
Must |
Must |
What a competitor can change to reduce risk
- Change sulfated sugar to a non-listed species (not hexasulfate/heptasulfate/octasulfate) or with pKa > 3.
- Avoid diethylammonium/triethylammonium during vesicle formation, or use different intravesicular counterions.
- Load irinotecan below phase transition temperature, or use a different loading mechanism not tied to that temperature threshold.
- Alter lipid composition away from DSPC:cholesterol 3:2.
- Fail the functional threshold: if encapsulation retention after 8h in mouse blood falls under 70%, the claim 11/13/14/17 “performance” pathway may not be met.
How does US 9,782,349 define key functional thresholds (≥85% loading and ≥70% 8-hour encapsulation)?
Loading threshold: “contacting at a temperature above phase transition” to load ≥85%
The only explicit quantitative loading threshold is ≥85% irinotecan loading into the lipid vesicle. Claim language makes the temperature-above-transition condition part of the process that yields that loading.
Enforcement implication
- A lab demonstration that a product reaches ≥85% loading without the temperature condition could undermine process-by-process coverage under Claim 1 path.
- If a competitor’s manufacturing sequence still results in the defined composition, Claim 11-type performance claims may still pose risk, depending on whether the product meets ≥70% retention.
Retention threshold: “≥70% remains encapsulated after 8 hours in blood of CD-1 mouse”
This is the single most enforceable numeric discriminator because it is tied to an in vivo test. It converts “liposome” from a general category into a specific performance profile.
Enforcement implication
- Any litigation will center on test comparability: sample prep, assay definition of “encapsulated,” and timepoint.
- The presence of the detailed assay method in Claim 12/16 suggests the patent-holder expects disputes on how encapsulation percentage is computed.
What does the detailed assay method in Claim 12 mean for infringement proof and lab disputes?
Claim 12 provides a full experimental workflow:
- Labeling: radioactive irinotecan liposomes
- Dose and administration: 10 mg/kg CPT-11 equivalent via tail vein in six-week-old female CD-1 mice
- Timepoint: 8 hours
- Blood handling: heparinized syringes; dilution buffer containing EDTA
- Centrifugation: 9,000 g for 5 minutes
- Quantification: fluorometric assay and quenching-corrected radioactivity scintillation counting with standards
- Computation: percent encapsulated based on drug/radioactivity ratios in plasma vs injected liposomes
Litigation relevance
- Claim 12 reads like a defined “claim construction aid” for what the patent considers correct encapsulation quantification.
- If accused products are tested using materially different protocols, defendants may argue measurement is not “the method comprising” steps as recited, affecting ability to satisfy the ≥70% standard for claims that rely on performance.
Patent landscape around US 9,782,349: what is likely protected beyond these claims?
Immediate protected subject matter within the claims
Based on the claim language alone, the protected space clusters into four tight pillars:
- Formulation concept: irinotecan encapsulated in liposomes with sulfated sugars
- Cargo conditioning: sulfated sugar plus substituted ammonium compounds in vesicle formation
- Loading method: temperature above lipid phase transition to achieve ≥85% loading
- In vivo retention: ≥70% encapsulation after 8 hours in CD-1 blood
Likely overlap risks for adjacent products
Any irinotecan liposome product that:
- uses sulfated sugars inside liposomes,
- and uses ammonium-containing internal environments during formulation,
- and relies on phase-transition-based loading,
- and demonstrates high mouse blood retention at the 8-hour window,
faces elevated claim-scope alignment.
Conversely, products that:
- use different internal gradients (e.g., sulfate gradients not relying on these specific ammonium compounds),
- use other lipids or lipid ratios,
- and fail the retention threshold,
create pathways to argue non-infringement.
How strong is the patent estate for irinotecan liposomes vs. typical generic design-around strategies?
Strength drivers embedded in the claim set
- Objective numeric thresholds: ≥85% loading and ≥70% retention. These reduce “hand-wavy” infringement arguments.
- Process-by-process framing for Claim 1 and detailed manufacturing elements.
- Specific chemical constraints: sulfated sugar identity and pKa ≤3; DSPC:chol 3:2.
- Assay methodology: Claim 12 and Claim 16 define measurement.
Strength limits embedded in the claim set
- Claim scope appears narrow around:
- sulfated sugar species and acid strength proxy,
- ammonium identity,
- phase transition loading,
- lipid composition ratio,
- and a mouse blood timepoint retention standard.
- A competitor can attempt non-infringement by shifting one or two of those levers.
Practical enforcement posture
- For compositions matching Claims 1/2/3/4/5/6/7/8/10, the patent-holder can target manufacturing records (process-by-process) and in vivo performance.
- For products matching Claim 11/13/14/17, the patent-holder can target performance testing and the defined encapsulation retention metric, potentially without proving the internal ammonium formation step if the claim construction treats performance as sufficient.
Key takeaways
- US Patent 9,782,349 centers on irinotecan liposomes with intraliposomal sulfated sugars and a loading scheme that requires contact above lipid phase transition temperature to reach ≥85% loading.
- The estate’s enforcement core is the in vivo functional threshold: ≥70% irinotecan remains encapsulated after 8 hours in CD-1 mouse blood.
- The most claim-tight design-around vectors are: (i) sulfated sugar identity/pKa, (ii) ammonium compound during vesicle formation, (iii) loading temperature regime, (iv) DSPC:cholesterol ratio.
- Claim 12 provides a detailed radioactive assay method, which can sharply influence proof and counter-proof around the “encapsulated” definition and the numeric ≥70% threshold.
FAQs
-
What in US 9,782,349 most directly drives infringement: the sulfated sugar identity or the 8-hour mouse blood retention test?
The strongest numeric discriminator is the ≥70% encapsulated after 8 hours requirement, with sulfated sugar/pKa and loading rules acting as major scoping filters.
-
Can a product that matches the 8-hour encapsulation retention avoid US 9,782,349 by using different ammonium compounds?
It depends on which claim path is asserted: Claim 11/13/14/17 do not explicitly require the ammonium formation step in the claim text, while Claim 1 and related process-bound claims do.
-
Does US 9,782,349 protect only DSPC:cholesterol liposomes?
No. DSPC:cholesterol 3:2 is only required in certain dependent claims (e.g., Claims 3, 8, 10, 14, 17). The broader independent Claim 1 is not limited to that ratio.
-
How can a competitor argue that the “temperature above phase transition” element is not met?
By demonstrating a loading process that operates at or below the lipid phase transition temperature or uses a loading mechanism not governed by that condition, then showing the resulting formulation does not meet the process-by-process Claim 1 construct.
-
What does Claim 12’s radioactive assay method mean for regulatory or CMC comparability studies?
It sets a defined testing framework for encapsulation quantification, so comparative studies that diverge materially in labeling, sampling, timing, or computation can become litigation focal points for whether the ≥70% standard is actually met.
References
- United States Patent 9,782,349. “Irinotecan liposome composition.” (Claims excerpt provided in prompt).
More… ↓
⤷ Start Trial
|
